Short answer · Medically reviewed summary · Last updated: 2026-04-07
Machado-Joseph Disease, also known as Spinocerebellar Ataxia Type 3 (SCA3), is classified under the ICD-10 code G11.2 (Spinocerebellar ataxia). In the older ICD-9 clinical modification system, it was categorized under 334.0 (Friedreich's ataxia) or 334.8 (Other spinocerebellar diseases), as specific coding for Machado-Joseph Disease did not exist as a unique entry. What is the clinical significance of these medical codes for Machado-Joseph Disease? Medical coding systems are essential for healthcare providers to document, track, and bill for services related to Machado-Joseph Disease.
Machado-Joseph Disease, also known as Spinocerebellar Ataxia Type 3 (SCA3), is classified under the ICD-10 code G11.2 (Spinocerebellar ataxia). In the older ICD-9 clinical modification system, it was categorized under 334.0 (Friedreich's ataxia) or 334.8 (Other spinocerebellar diseases), as specific coding for Machado-Joseph Disease did not exist as a unique entry.
Medical coding systems are essential for healthcare providers to document, track, and bill for services related to Machado-Joseph Disease. Because this condition is a rare, autosomal dominant neurodegenerative disorder, precise coding ensures that patients receive appropriate insurance coverage for specialized care, such as physical therapy, speech therapy, and neurology consultations. While ICD-10 code G11.2 is the primary designation used globally, it is important to note that it captures a broader category of hereditary ataxias, meaning that diagnostic confirmation via genetic testing remains the gold standard for identifying Machado-Joseph Disease specifically.
Diagnosis of Machado-Joseph Disease is primarily achieved through molecular genetic testing, which identifies an abnormal expansion of CAG trinucleotide repeats in the ATXN3 gene on chromosome 14q32.1. Before genetic testing, neurologists typically perform a clinical examination to assess for hallmark symptoms, including gait ataxia, ophthalmoplegia (eye movement difficulties), and dystonia. At DiseaseMaps.org, 42 people with Machado-Joseph Disease have shared their experiences, highlighting the diverse age of onset, which typically occurs between 20 and 50 years of age.
The progression of Machado-Joseph Disease is highly variable, even within families, often depending on the length of the CAG repeat expansion. Clinicians generally classify the symptoms into distinct types based on the age of onset and the predominant neurological features present. Common clinical manifestations include:
Yes, Machado-Joseph Disease follows an autosomal dominant pattern of inheritance. This means that an affected individual has a 50% chance of passing the expanded ATXN3 gene to each of their children. Genetic counseling is strongly recommended for families affected by Machado-Joseph Disease to discuss the implications of genetic testing, the phenomenon of anticipation (where the age of onset may be earlier in successive generations), and reproductive options.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician regarding any medical condition.